Skip to main content

Manuel Comabella Lopez

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia
Manuel Comabella Lopez

Manuel Comabella Lopez

Manuel Comabella Lopez

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

From 1996 to 1998, Dr. Manuel Comabella was a Research Fellow in Neuroimmunology at the Center for Neurologic Diseases, Brigham and Women´s Hospital, in Boston. In 2010 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. In 2011 was awarded by the Spanish Society of Neurology (SEN) with the Biogen Idec Prize to the best publication on demyelinating disorders. In 2013 was awarded by the SEN with the Novartis Prize to the best oral communication and the best publication on demyelinating disorders. In 2014 received the Neurological Disorders Award, scientific modality, granted by the SEN. In 2016 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. From 2018 to 2020, Dr. Manuel Comabella was a collaborator of the Biomedicine area at the Division of Coordination, Evaluation and Scientific and Technical Follow-up of the State Research Agency, Ministry of Science, Innovation and Universities.

Dr. Manuel Comabella is member of the Editorial Board of Journal of Neuroimmunology and Multiple Sclerosis Journal, member of the Board of the ESNI (European School of Neuroimmunology), and member of the Strategic Group of the IMSGC (International Multiple Sclerosis Genetics Consortium). He is coauthor of 297 documents indexed in MedLine (Scopus: 12916 total citations, with h-index of 54). Dr. Manuel Comabella's research interest lies in the identification of biomarkers related with different aspects of multiple sclerosis and the development of new therapeutic strategies for the disease.

Projects

Red de investigación en inflammasoma y piroptosis en enfermedades crónicas y cáncer

IP: Manuel Comabella Lopez
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: RED2022-134511-T
Duration: 01/06/2023 - 31/05/2025

Ministerio de Ciencia

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Teresa Macarulla Mercadé, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Ana Vivancos Prellezo, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Paolo Giovanni Nuciforo, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

Complicacions neurològiques associades a cèl·lules CAR-T (CAR-T: Chimeric Antigen Receptor T-cell)

IP: Manuel Comabella Lopez
Collaborators: Andreu Vilaseca Jolonch, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 35000
Reference: HUVH/BPFSE_CM/2022/VILASECA
Duration: 01/06/2022 - 31/05/2023

Incorporación al CIBER de enfermedades neurodegenerativas como grupo de esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Jordi Rio Izquierdo, Carmen Tur Gomez, Xavier Montalban Gairín, Luciana Midaglia Fernandez, Joaquin Castillo Justribo, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Instituto de Salud Carlos III
Funding: 48000
Reference: CB22/05/00047
Duration: 13/12/2022 - 12/12/2023

Related news

The second edition of the AI ​​Day served to share knowledge, reflect and chart the future of artificial intelligence applied to research and health.

The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Related professionals

Montserrat García Portabella

Montserrat García Portabella

Reconstructive Surgery of the Locomotor System
Read more
Manuel Jesus Iglesias Cabezas

Manuel Jesus Iglesias Cabezas

Predoctoral researcher
Microbiology
Read more
Sonia Galindo Maycas

Sonia Galindo Maycas

Research technician
Infection and immunity in pediatric patients
Read more
Blanca  Borras  Bermejo

Blanca Borras Bermejo

Predoctoral researcher
Epidemiology and Public Health
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.